[ad_1]
Vaccination Institute in collaboration with Siriraj – Chula – Science Department Develop a prototype vaccine. Testing on experimental animals and coordination of “China” to collaborate in research.
Now, no one can predict the Covid-19 virus. How long will it be with the world? Hope is directed to the “vaccine” against Covid-19. Dr. Nakorn Premsri, MD. Director of the National Vaccine Institute. (Public organization) said that the National Institute of Vaccines are collaborating in the development of a prototype interdepartmental vaccine, namely research from the Faculty of Medicine, Chulalongkorn with the company Bionet-Asia and the Faculty of Medicine of the Siriraj Faculty Hospital of Sciences Mahidol University And the Faculty of Pharmacy Chulalongkorn University
Currently in animal testing. Before entering the test in person Lead to the production of vaccines by yourself within the country. This will allow faster access to the vaccine. It is an important basis for dealing with emerging infectious diseases in the future too
Including coordination with foreign countries in the “vaccine” study to test in Thailand. Especially with the Chinese embassy Monitoring the progress of the cooperation agreement with China. Participation in research, testing and vaccination of people in phase 2
Dr. Supapaporn Phumamorn Director of the Institute of Biological Materials. Department of Medical Sciences said that the Department of Medical Sciences now undergo blood tests. From experimental animals that received 2 research prototype vaccines from the Chulalongkorn University School of Medicine With the company Bionet-Asia
As for the research of the Faculty of Medicine of the Siriraj Hospital Faculty of science Mahidol University And the faculty of pharmacy Chulalongkorn University In the process of increasing the amount of virus To be disinfected It is a lethal vaccine To be injected into experimental animals.
The development of the vaccine. After testing on experimental animals. The efficacy of the vaccine will be tested in 3 stages: phase 1 safety tests in 30-50 people, phase 2 immunization for small groups of 100 to 150 people and phase 3 results in disease prevention in large groups of 500 people. Up
Add friend Follow
[ad_2]
